News/ News/ R&D CHMP clears way for EU approval of Novartis’ MS drug Richard Staines CHMP, GlaxoSmithKline, multiple sclerosis, Novartis, ofatumumab 0 Comment Novartis’ multiple sclerosis drug has been given the green light by the European Medicines Agency’s CHMP scientific committee, Share X CHMP clears way for EU approval of Novartis’ MS drug https://pharmaphorum.com/news/chmp-clears-way-for-eu-approval-for-novartis-ms-drug/
News/ News/ R&D FDA extends review of Novartis’ MS drug ofatumumab Richard Staines fda, multiple sclerosis, Novartis, ofatumumab, R&D, Roche 0 Comment The FDA has extended its review of Novartis’ potential multiple sclerosis drug ofatumumab, pushing back a decision on the repurposed Share X FDA extends review of Novartis’ MS drug ofatumumab https://pharmaphorum.com/news/fda-extends-review-of-novartis-ms-drug-ofatumumab/
CHMP, GlaxoSmithKline, multiple sclerosis, Novartis, ofatumumab
0 Comment
